Bruker Corp. (BRKR) has agreed to pay AbCellera Biologics (ABCL) $36 million plus future royalties as part of a settlement over a patent dispute concerning microfluidic devices. This resolution follows a federal appeals court decision rejecting Bruker's prior art claim on AbCellera's patent. The news has positively impacted AbCellera's stock, which rose approximately 8% in Thursday morning trading.
https://www.gurufocus.com/news/4076156/bruker-brkr-agrees-to-36m-settlement-with-abcellera-abcl
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.